Rebinding drives cellular retention of small-molecule drugs with abundant targets
Open Access
- 19 May 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Abstract
Many small-molecule antitumor drugs are administered far less frequently than would be predicted from their plasma half-lives, in part because their efficacy is driven by prolonged retention within tumors. Drug retention can be caused by nonspecific protein binding, low membrane permeability, sequestration in acidic compartments, slow target dissociation, and rebinding to empty target sites, but the field has lacked a quantitative framework and preclinical assays for discriminating these mechanisms and predicting retention in vivo. We developed a theoretical framework and a simple two-drug assay for quantifying retention mechanisms in cell-based models. Application to 13 drugs with 8 distinct intracellular targets revealed diverse retention mechanisms. Rebinding emerged as a potent driver of retention whose magnitude was predicted by the target-to-affinity ratio ([Target]/ K d ). Rebinding slows the washout rates of important drugs such as taxanes and rapamycin by 100-fold or more. It also explains the need for high loading concentrations. Our approach bridges a critical gap in pharmacology modeling and provides practical tools to guide the design of intermittent dosing regimens.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM131753)
This publication has 44 references indexed in Scilit:
- PaxDb 5.0: Curated Protein Quantification Data Suggests Adaptive Proteome Changes in YeastsMolecular & Cellular Proteomics, 2023
- Optimizing the future: how mathematical models inform treatment schedules for cancerTrends in Cancer, 2022
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Concept of Pharmacologic Target‐Mediated Drug Disposition in Large‐Molecule and Small‐Molecule CompoundsThe Journal of Clinical Pharmacology, 2019
- Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kineticsCurrent Opinion in Chemical Biology, 2019
- Importance of target-mediated drug disposition for small moleculesDrug Discovery Today, 2018
- Pharmacokinetics and the drug–target residence time conceptDrug Discovery Today, 2013
- Retention of paclitaxel in cancer cells for 1 week in vivo and in vitroCancer Chemotherapy and Pharmacology, 2006
- Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micellesCancer Chemotherapy and Pharmacology, 2001
- Diffusion Control in Biochemical Reactions1974